The rejection of Sarepta Therapeutics Inc.’s proposed Duchenne muscular dystrophy therapy golodirsen caught investors and patients very much by surprise, and has thus become the latest rallying point for calls to make US Food and Drug Administration “complete response” letters public.
As is usually the case, Sarepta is declining to release the letter – though the company’s explanation that it would...